AstraZeneca has presented new analyzes of the Pegasus-Timi 54 trial in the framework of the Scientific Conferences of the American Heart Association. These findings contribute to advance the clinical knowledge of the role of double antiplatelet therapy in the treatment of patients after myocardial infarction (MI) after the first 12 months of treatment for acute coronary syndrome (ACS).
These latter subanalyses of the trial provide new data on the strategy for selecting patients who can achieve a greater reduction in major cardiovascular events (MACE) through prolonged treatment with ticagrelor (60 mg), with a risk absolute minor of severe hemorrhage than the total study cohort.
A second subanalysis presented during the congress highlights the possible benefit of ticagrelor treatment in the long-term treatment of post-MI patients, regardless of the history of coronary stent implantation.
Elisabeth Björk, vice president and director of Cardiovascular, Kidney and Metabolic Diseases of the Department of Global Drug Development of AstraZeneca said that “the studies presented during the AHA days reinforce the role that ticagrelor can play in reducing persistent and long risk term of cardiovascular events in patients with a history of MI. In addition, these data represent another tool that will help health professionals identify the most appropriate patients for treatment. ”
Distefar supports these findings that contribute to advancing the clinical knowledge of the role of double antiplatelet therapy in the treatment of post-myocardial infarction patients.